B
RMTI icon

Bailard’s Rockwell Medical RMTI Stock Holding History

Bailard’s Portfolio RMTI Stock Details RMTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,284
Closed -$289K – 810
2024
Q3 		$289K Buy
+7,284
New +$196K 0.01% 589

Other funds holding RMTI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bailard's RMTI Position: Q4 2024 in Review

Bailard sold out of Rockwell Medical (RMTI) in Q4 2024, closing a stake of 7,284 shares — an estimated $289K sold.

Bailard first reported a position in RMTI in Q3 2024 and held it in 1 quarter. The position peaked at $289K in Q3 2024. 53 funds tracked by Wall St. Rank hold RMTI as of Q4 2024.

  • Bailard reported no remaining Rockwell Medical position as of Q4 2024 after selling out during the quarter.
  • Bailard sold 7,284 Rockwell Medical shares in Q4 2024, an estimated $289K.
  • Bailard first reported a position in Rockwell Medical in Q3 2024 and held it in 1 quarter.
  • Bailard's Rockwell Medical position peaked at $289K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Rockwell Medical as of Q4 2024.

Based on Bailard's 13F filing for Q4 2024, filed 5 Feb 2025.